Drugs / 68Ga-DOTATATE

Trials 25 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 06 trials
Phase 0 NCT05069220 Sep 2021 → Sep 2025 overdue neuroblastoma, paraganglioma, pheochromocytoma Peking Union Medical College Hospital Recruiting No outcome recorded
Phase 0 NCT04040088 Sep 2019 → Jul 2026 overdue ganglioneuroblastoma, ganglioneuroma, neuroblastoma Mayo Clinic Active not recruiting No outcome recorded
Phase 0 NCT03623984 Jun 2019 → Jun 2022 carcinoid tumor, pancreatic endocrine carcinoma University of Alabama at Birmingham Withdrawn No outcome recorded
Phase 0 NCT04041882 Apr 2014 → Dec 2020 neuroendocrine neoplasm Peking Union Medical College Hospital Unknown No outcome recorded
Phase 0 NCT01873248 Aug 2013 → Jun 2017 neuroendocrine neoplasm Jonsson Comprehensive Cancer Center Completed No outcome recorded
Phase 0 NCT01524016 Dec 2011 → Dec 2017 Oncogenic osteomalacia, mesenchymal cell neoplasm Peking Union Medical College Hospital Unknown No outcome recorded
Phase 12 trials
Phase 1 NCT06520319 Jun 2023 → Dec 2024 overdue medullary thyroid gland carcinoma First Affiliated Hospital of Fujian Medical University Recruiting No outcome recorded
Phase 1 NCT04689893 Mar 2020 → Mar 2021 Oncogenic osteomalacia Peking Union Medical College Hospital Unknown No outcome recorded
Phase 1/25 trials
Phase 1/2 NCT05990998 Nov 2022 → Aug 2023 First Affiliated Hospital of Fujian Medical University Completed No outcome recorded
Phase 1/2 NCT03736564 Jan 2019 → Oct 2023 osteomalacia Mayo Clinic Completed No outcome recorded
Phase 1/2 NCT03648073 Jan 2019 → Feb 2022 hepatocellular carcinoma University of Alabama at Birmingham Completed No outcome recorded
Phase 1/2 NCT02038738 Mar 2014 → Mar 2019 adenoma, carcinoid tumor, neuroendocrine carcinoma, neuroendocrine disorder +1 Ochsner Health System Unknown No outcome recorded
Phase 1/2 NCT02078843 Mar 2014 → Aug 2016 digestive system neuroendocrine neoplasm Insel Gruppe AG, University Hospital Bern Terminated No outcome recorded
Phase 26 trials
Phase 2 NCT07284589 Dec 2025 → Apr 2030 expected neuroendocrine neoplasm Akiva Mintz Recruiting No outcome recorded
Phase 2 NCT05880394 Jan 2023 → Jul 2024 breast cancer Hoag Memorial Hospital Presbyterian Unknown No outcome recorded
Phase 2 NCT04559217 Dec 2021 → Dec 2027 expected neuroblastoma Centre de recherche du Centre hospitalier universitaire de Sherbrooke Recruiting No outcome recorded
Phase 2 NCT03448458 Feb 2018 → Feb 2023 castration-resistant prostate carcinoma, metastatic prostate carcinoma Emory University Completed No outcome recorded
Phase 2 NCT02019706 Feb 2014 → Dec 2030 expected ectopic Cushing syndrome National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Recruiting No outcome recorded
Phase 2 NCT00001277 Dec 1993 → Mar 2020 hypercalcemia disease, multiple endocrine neoplasia type 1 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Completed No outcome recorded
Phase 31 trial
Phase 3 NCT04043377 Nov 2019 → Sep 2021 coronary atherosclerosis Assistance Publique - Hôpitaux de Paris Terminated No outcome recorded
Phase 41 trial
Phase 4 NCT03549598 Jul 2018 → Oct 2019 cardiac sarcoidosis Mayo Clinic Completed No outcome recorded
Phase not applicable2 trials
NCT02546388 Oct 2015 → Aug 2018 cardiac sarcoidosis Marcelo F. Di Carli, MD, FACC Completed No outcome recorded
NCT01879657 Mar 2013 → Dec 2015 neuroendocrine carcinoma Radio Isotope Therapy of America Completed No outcome recorded
Phase not stated2 trials
NCT02174679 carcinoid tumor, medullary thyroid gland carcinoma Jonsson Comprehensive Cancer Center No longer available No outcome recorded
NCT01980732 carcinoid tumor, pancreatic neuroendocrine tumor Andrei Iagaru No longer available No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 25 sources stand behind the page.

FieldValueCited text
Known as 68Ga-DOTATATE “Each patient received a single intravenous injection of 68Ga-DOTATATE (2-4 mCi) and underwent PET/CT scanning 40-60 minutes after the injection.” NCT06520319
19

“Participants will be injected with 68Ga-DOTATATE and imaged for up to 3 hours on a PET scanner” NCT07284589

“Subjects will undergo imaging by 68Ga-DOTATATE PET/CT” NCT03736564

NCT01873248

NCT04043377

NCT01524016

NCT04559217

NCT07284589

NCT03549598

NCT05990998

NCT04689893

NCT00001277

NCT03648073

NCT01980732

NCT02019706

NCT04041882

NCT02174679

NCT05069220

NCT01879657

NCT02038738

Known as 68Ga-MGS5 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06520319
Known as Gallium Dotatate ClinicalTrials.gov intervention name — accepted as the source's own label NCT03623984
Known as Gallium Ga 68-DOTATATE ClinicalTrials.gov intervention name — accepted as the source's own label NCT03448458
1

NCT04040088

Known as Gallium-68 (68Ga)-Dotatate “The radiotracer, Gallium-68 (68Ga)-Dotatate, is FDA-approved for detecting neuroendocrine cancer at standard doses.” NCT07284589
Known as Gallium-68 Dotatate Gallium-68 Dotatate, a radioactive imaging agent, is injected into a vein.” NCT03736564
3

NCT02078843

NCT05880394

NCT02546388

Modality Diagnostic / imaging agent “Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA” NCT00001277
Route Intravenous Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution” NCT01524016
Target SSTR2 “high affinity and selectivity for somatostatin receptor 2 (SSTR 2)” NCT04043377